Pharmacological Effects of the Ruthenium Complex NAMI-A Given Orally to CBA Mice With MCa Mammary Carcinoma

NAMI-A, imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate, is a ruthenium based compounds capable of inhibiting the growth of lung metastases of solid tumours in a number of experimental conditions.The aim of this study was to investigate the potential use of NAMI-A by the oral route to treat lung metastases of MCa mammary carcinoma in the CBA mouse. treatment of mice, carrying intramuscular tumours in advanced stage of growth, for 11 consecutive days caused a significant reduction of the weight of lung metastases over the range of doses from 150 to 600 mg/kg/day. No sign of toxicity was observed at the histological analysis in the gut epithelium or in the kidney parenchyma, and NAMI-A concentration in the kidney was more than 10-fold lower than after intraperitoneal treatments. NAMI-A is thus active against metastases also by the oral route, suggesting the use of this way to treat tumour bearing hosts for long periods.

• Publication year

  2001

• Venue

  Metal-Based Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1155/MBD.2001.1PMID 18475970PMCID 2365250
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-cancer drugs

  2012cited by this paper

• Exploring the coordination chemistry of ruthenium complexes with lysozymes: structural and in-solution studies

  2024cites this paper
• Three novel complexes of copper: synthesis, characterization, crystal structure, HSA-binding and docking studies, and antiproliferative activity

  2020cites this paper
• Development, evaluation and effect of anionic co-ligand on the biological activity of benzothiazole derived copper(II) complexes.

  2020cites this paper
• Reaction mechanism of NO with hydrolysates of NAMI‐A: an MD simulation by combining the QM/MM(ABEEM) with the MD‐FEP method

  2018cites this paper
• Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.

  2018cites this paper
• RuIII Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic

  2017cites this paper
• Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.

  2016cites this paper
• Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.

  2016cites this paper
• Metal-Assisted Activation of Nitric Oxide—Mechanistic Aspects of Complex Nitrosylation Processes

  2015cites this paper
• In vivo evaluation of small-molecule thermoresponsive anticancer drugs potentiated by hyperthermia

  2015cites this paper
• Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.

  2015cites this paper
• Quantum Chemical Studies on Detail Mechanism of Nitrosylation of NAMI-A-HSA Adduct.

  2015cites this paper
• Thermoresponsive fluorinated small-molecule drugs: a new concept for efficient localized chemotherapy

  2015cites this paper
• Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells

  2014cites this paper
• Binuclear copper complexes: synthesis, X-ray structure and interaction study with nucleotide/protein by in vitro biochemical and electrochemical analysis.

  2014cites this paper
• Synthesis, characterization, and anti-cancer activity of emodin-Mn(II) metal complex.

  2014cites this paper
• Interaction of the NAMI-A complex with nitric oxide under physiological conditions

  2014cites this paper
• Synthesis, crystal structure, DNA interaction and anticancer activity of tridentate copper(II) complexes.

  2013cites this paper
• Synthesis, characterization antibacterial and antifungal activity of some transition metal complexes

  2013cites this paper
• Efficient DNA cleavage mediated by mononuclear mixed ligand copper(II) phenolate complexes: the role of co-ligand planarity on DNA binding and cleavage and anticancer activity.

  2012cites this paper
• Mixed ligand copper(II) complexes of N,N-bis(benzimidazol-2-ylmethyl)amine (BBA) with diimine co-ligands: efficient chemical nuclease and protease activities and cytotoxicity.

  2012cites this paper
• Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin.

  2012cites this paper
• Synthesis, spectroscopic characterization and in vitro antitumor activities of some novel mononuclear Ru(II) complexes

  2012cites this paper
• Preparation of hexacoordinating benzimidazole containing ligand and hexakis(benzimidazole-ruthenium(II)) complex. Molecular structure of C6{CH2-(N-benzimidazole-RuCl2(p-cymene))}6.

  2011cites this paper
• Original article SYNTHESIS, CHARACTERIZATION AND CYTOTOXIC ACTIVITY OF SOME Ru(II) COMPLEXES

  2011cites this paper
• Interaction of rac-[M(diimine)3]2+ (M=Co, Ni) complexes with CT DNA: role of 5,6-dmp ligand on DNA binding and cleavage and cytotoxicity.

  2011cites this paper
• SYNTHESIS, CHARACTERIZATION AND CYTOTOXIC ACTIVITY OF SOME Ru(II) COMPLEXES

  2011cites this paper
• Cytotoxicity, Apoptosis, Cellular Uptake, Cell Cycle Arrest, Photocleavage, and Antioxidant Activity of 1, 10-Phenanthroline Ruthenium(II) Complexes

  2011cites this paper
• Ternary dinuclear copper(II) complexes of a hydroxybenzamide ligand with diimine coligands: the 5,6-dmp ligand enhances DNA binding and cleavage and induces apoptosis.

  2011cites this paper
• Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.

  2011cites this paper
• In Vitro Cytotoxicity, Apoptosis, DNA-Binding, and Antioxidant Activity Studies of Ruthenium (II) Complexes

  2010cites this paper
• Bis(2,9-dimethyl-1,10-phenanthroline-κ2 N,N′)(10,11,12,13-tetrahydrodipyrido[3,2-a:2′,3′-c]phenazine-κ2 N 4,N 5)ruthenium(II) bis(perchlorate) dihydrate

  2010cites this paper
• Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes

  2010cites this paper
• 2-(3,5-Dibromo-4-hydroxyphenyl)imidazo[4,5-f][1,10]phenanthrolinoruthenium(II) complexes: synthesis, characterization, cytotoxicity, apoptosis, DNA-binding and antioxidant activity

  2010cites this paper
• Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.

  2008cites this paper
• Mixed ligand ruthenium(II) complexes of bis(pyrid-2-yl)-/bis(benzimidazol-2-yl)-dithioether and diimines: study of non-covalent DNA binding and cytotoxicity.

  2008cites this paper
• Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.

  2007cites this paper
• Synthesis and characterization of ionic Ru(III) complexes containing dimethylsulfoxide and dinitrogen heterocyclic ligands

  2007cites this paper
• In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

  2005cites this paper
• Primary Tumor, Lung and Kidney Retention and Antimetastasis Effect of NAMI-A Following Different Routes of Administration

  2003cites this paper
• Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.

  2003cites this paper